Craig Gulliford (CG), chief executive of Creo Medical Group PLC (AIM:CREO), joined Proactive's Stephen Gunnion (SG) to delve into the deployment of its Speedboat UltraSlim device in the Asia Pacific region.
The Speedboat UltraSlim, a culmination of years of development, miniaturises laparoscopic advanced energy capabilities into a compact device enhancing endoscopic surgery.
This innovation enables precise surgical procedures with minimal invasiveness, targeting precancerous and cancerous lesions in the gastrointestinal tract.
Here’s what Gulliford had to say:
SG: Craig, can you share the significance of deploying the Speedboat UltraSlim device in the Asia Pacific region?
CG: The deployment of the Speedboat UltraSlim in the Asia Pacific is a testament to years of dedication in miniaturising laparoscopic advanced energy capabilities. This device, smaller than a ballpoint pen's tip, revolutionises endoscopic surgery, allowing for precise procedures with minimal invasiveness. It's designed for targeting precancerous and cancerous lesions in the gastrointestinal tract, significantly reducing the need for conventional surgery and lowering complication rates.
SG: What makes the Speedboat UltraSlim a pivotal development in medical technology?
CG: The Speedboat UltraSlim embodies the culmination of our efforts to enhance laparoscopic surgical capabilities in a compact form. It brings advanced energy capabilities directly to endoscopists, who previously relied on outdated diathermy technology. With its development complete, we're now able to focus on broadening its applications and ensuring it can be used with all types of endoscopes, making it more accessible and user-friendly for physicians.
SG: How has the Speedboat UltraSlim been received in clinical applications across different regions?
CG: We've implemented a phased market release, initially focusing on both complex and straightforward cases in the gastrointestinal areas within the US, moving through South America, Europe, and most recently, the Asia Pacific. Each step allowed us to test the device across a variety of clinical indications, ensuring its efficacy and safety before widespread commercialization.
SG: Can you highlight the impact of the Speedboat UltraSlim in specific medical procedures?
CG: Absolutely. The device is particularly effective in treating lower GI precancerous and cancerous lesions, aiming to eliminate the necessity for surgery in many cases. It's also used in upper GI for treating gastric lesions with lower complication rates. An impressive example includes its application in endoscopic procedures replacing more invasive surgeries, such as the fundoplication used in bariatric surgery, showcasing our technology's versatility and safety.
SG: Creo also announced a collaboration with Khalifa University of Science and Technology. What does this partnership entail?
CG: Our strategic collaboration with Khalifa University aims to develop intellectual property and expand our technological reach, particularly in the Middle East. This partnership allows us to leverage our rich IP portfolio and collaborate on research projects that could lead to significant commercial and clinical outcomes. It's a step towards enhancing medical outcomes and innovation, in line with our commitment to improving patient care globally.
SG: What future developments can we expect from Creo Medical in advancing medical technology?
CG: We're focused on broadening the application of our core technologies, including the Speedboat UltraSlim, and enhancing our presence in key markets like the Middle East. Through collaborations and our ongoing research and development efforts, we aim to introduce more innovations that will continue to transform patient care and clinical practices worldwide.